APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-Hodgkin's Lymphoma Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Non-Hodgkin's Lymphoma Drug Market Outlook and Growth Opportunities 2026

2 January 2026191 pages

Choose your research edition.

Industry ResearchNon-Hodgkin's Lymphoma Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-Hodgkin's Lymphoma Drug Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Non-Hodgkin's Lymphoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-Hodgkin's Lymphoma Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-Hodgkin's Lymphoma Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Non-Hodgkin's Lymphoma Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Non-Hodgkin's Lymphoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Non-Hodgkin's Lymphoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Non-Hodgkin's Lymphoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Non-Hodgkin's Lymphoma Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Non-Hodgkin's Lymphoma Drug market include Acrotech Biopharma, Eagle Pharmaceuticals, Epizyme, Gilead Sciences, MundiPharma, Secura Bio, TG Therapeutics, Bayer and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Non-Hodgkin's Lymphoma Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Non-Hodgkin's Lymphoma Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Non-Hodgkin's Lymphoma Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Non-Hodgkin's Lymphoma Drug market.

Non-Hodgkin's Lymphoma Drug Segment by Company

Acrotech Biopharma

Eagle Pharmaceuticals

Epizyme

Gilead Sciences

MundiPharma

Secura Bio

TG Therapeutics

Bayer

Roche

Teva

Eisai

Non-Hodgkin's Lymphoma Drug Segment by Type

Oral

Injection

Non-Hodgkin's Lymphoma Drug Segment by Application

Hospital

Retail Pharmacy

Other

Non-Hodgkin's Lymphoma Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Non-Hodgkin's Lymphoma Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Non-Hodgkin's Lymphoma Drug key companies, revenue, market share, and recent developments.

3. To split the Non-Hodgkin's Lymphoma Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Non-Hodgkin's Lymphoma Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Non-Hodgkin's Lymphoma Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Non-Hodgkin's Lymphoma Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-Hodgkin's Lymphoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-Hodgkin's Lymphoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-Hodgkin's Lymphoma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Non-Hodgkin's Lymphoma Drug industry.

Chapter 3: Detailed analysis of Non-Hodgkin's Lymphoma Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Non-Hodgkin's Lymphoma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Non-Hodgkin's Lymphoma Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Non-Hodgkin's Lymphoma Drug Industry Trends Table 2. Non-Hodgkin's Lymphoma Drug Industry Drivers Table 3. Non-Hodgkin's Lymphoma Drug Industry Opportunities and Challenges Table 4. Non-Hodgkin's Lymphoma Drug Industry Restraints Table 5. Global Non-Hodgkin's Lymphoma Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Non-Hodgkin's Lymphoma Drug Revenue Share by Company (2021-2026) Table 7. Global Non-Hodgkin's Lymphoma Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Non-Hodgkin's Lymphoma Drug Key Company Manufacturing Base & Headquarters Table 9. Global Non-Hodgkin's Lymphoma Drug Company, Product Type & Application Table 10. Global Non-Hodgkin's Lymphoma Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Non-Hodgkin's Lymphoma Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oral Table 15. Significant Companies of Injection Table 16. Global Non-Hodgkin's Lymphoma Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Non-Hodgkin's Lymphoma Drug Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Non-Hodgkin's Lymphoma Drug Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Non-Hodgkin's Lymphoma Drug Sales Value Share by Type (2021-2026) Table 20. Global Non-Hodgkin's Lymphoma Drug Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Retail Pharmacy Table 23. Significant Companies of Other Table 24. Global Non-Hodgkin's Lymphoma Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Non-Hodgkin's Lymphoma Drug Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Non-Hodgkin's Lymphoma Drug Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Non-Hodgkin's Lymphoma Drug Sales Value Share by Application (2021-2026) Table 28. Global Non-Hodgkin's Lymphoma Drug Sales Value Share by Application (2027-2032) Table 29. Global Non-Hodgkin's Lymphoma Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Non-Hodgkin's Lymphoma Drug Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Non-Hodgkin's Lymphoma Drug Sales Value Share by Region (2021-2026) Table 32. Global Non-Hodgkin's Lymphoma Drug Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Non-Hodgkin's Lymphoma Drug Sales Value Share by Region (2027-2032) Table 34. Global Non-Hodgkin's Lymphoma Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Non-Hodgkin's Lymphoma Drug Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Non-Hodgkin's Lymphoma Drug Sales Value Market Share by Country (2021-2026) Table 37. Global Non-Hodgkin's Lymphoma Drug Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Non-Hodgkin's Lymphoma Drug Sales Value Market Share by Country (2027-2032) Table 39. Acrotech Biopharma Company Information Table 40. Acrotech Biopharma Business Overview Table 41. Acrotech Biopharma Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Acrotech Biopharma Non-Hodgkin's Lymphoma Drug Product Portfolio Table 43. Acrotech Biopharma Recent Development Table 44. Eagle Pharmaceuticals Company Information Table 45. Eagle Pharmaceuticals Business Overview Table 46. Eagle Pharmaceuticals Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Eagle Pharmaceuticals Non-Hodgkin's Lymphoma Drug Product Portfolio Table 48. Eagle Pharmaceuticals Recent Development Table 49. Epizyme Company Information Table 50. Epizyme Business Overview Table 51. Epizyme Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Epizyme Non-Hodgkin's Lymphoma Drug Product Portfolio Table 53. Epizyme Recent Development Table 54. Gilead Sciences Company Information Table 55. Gilead Sciences Business Overview Table 56. Gilead Sciences Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Gilead Sciences Non-Hodgkin's Lymphoma Drug Product Portfolio Table 58. Gilead Sciences Recent Development Table 59. MundiPharma Company Information Table 60. MundiPharma Business Overview Table 61. MundiPharma Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. MundiPharma Non-Hodgkin's Lymphoma Drug Product Portfolio Table 63. MundiPharma Recent Development Table 64. Secura Bio Company Information Table 65. Secura Bio Business Overview Table 66. Secura Bio Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Secura Bio Non-Hodgkin's Lymphoma Drug Product Portfolio Table 68. Secura Bio Recent Development Table 69. TG Therapeutics Company Information Table 70. TG Therapeutics Business Overview Table 71. TG Therapeutics Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. TG Therapeutics Non-Hodgkin's Lymphoma Drug Product Portfolio Table 73. TG Therapeutics Recent Development Table 74. Bayer Company Information Table 75. Bayer Business Overview Table 76. Bayer Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Bayer Non-Hodgkin's Lymphoma Drug Product Portfolio Table 78. Bayer Recent Development Table 79. Roche Company Information Table 80. Roche Business Overview Table 81. Roche Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Roche Non-Hodgkin's Lymphoma Drug Product Portfolio Table 83. Roche Recent Development Table 84. Teva Company Information Table 85. Teva Business Overview Table 86. Teva Non-Hodgkin's Lymphoma Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Teva Non-Hodgkin's Lymphoma Drug Product Portfolio Table 88. Teva Recent Development Table 89. Eisai Company Information Table 90. Eisai Business Overview Table 91. Eisai Non-Hodgkin's Lymphoma Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Eisai Non-Hodgkin's Lymphoma Drug Product Portfolio Table 93. Eisai Recent Development Table 94. Research Programs/Design for This Report Table 95. Authors List of This Report Table 96. Secondary Sources Table 97. Primary Sources List of Figures Figure 1. Non-Hodgkin's Lymphoma Drug Product Image Figure 2. Global Non-Hodgkin's Lymphoma Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-Hodgkin's Lymphoma Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Non-Hodgkin's Lymphoma Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oral Image Figure 8. Injection Image Figure 9. Global Non-Hodgkin's Lymphoma Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Non-Hodgkin's Lymphoma Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Non-Hodgkin's Lymphoma Drug Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Retail Pharmacy Image Figure 14. Other Image Figure 15. Global Non-Hodgkin's Lymphoma Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Non-Hodgkin's Lymphoma Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Non-Hodgkin's Lymphoma Drug Sales Value Share by Application (2021-2032) Figure 18. Global Non-Hodgkin's Lymphoma Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Non-Hodgkin's Lymphoma Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032) & (US$ Million) Figure 21. North America Non-Hodgkin's Lymphoma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Non-Hodgkin's Lymphoma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Non-Hodgkin's Lymphoma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032) & (US$ Million) Figure 27. South America Non-Hodgkin's Lymphoma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Non-Hodgkin's Lymphoma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Acrotech Biopharma
  • Eagle Pharmaceuticals
  • Epizyme
  • Gilead Sciences
  • MundiPharma
  • Secura Bio
  • TG Therapeutics
  • Bayer
  • Roche
  • Teva
  • Eisai

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Non-Hodgkin's Lymphoma Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Non-Hodgkin's Lymphoma Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Non-Hodgkin's Lymphoma Drug Market Dynamics
  1. 2.1 Non-Hodgkin's Lymphoma Drug Industry Trends
  2. 2.2 Non-Hodgkin's Lymphoma Drug Industry Drivers
  3. 2.3 Non-Hodgkin's Lymphoma Drug Industry Opportunities and Challenges
  4. 2.4 Non-Hodgkin's Lymphoma Drug Industry Restraints
3 Non-Hodgkin's Lymphoma Drug Market by Company
  1. 3.1 Global Non-Hodgkin's Lymphoma Drug Company Revenue Ranking in 2025
  2. 3.2 Global Non-Hodgkin's Lymphoma Drug Revenue by Company (2021-2026)
  3. 3.3 Global Non-Hodgkin's Lymphoma Drug Company Ranking (2024-2026)
  4. 3.4 Global Non-Hodgkin's Lymphoma Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Non-Hodgkin's Lymphoma Drug Company Product Type and Application
  6. 3.6 Global Non-Hodgkin's Lymphoma Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Non-Hodgkin's Lymphoma Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Non-Hodgkin's Lymphoma Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Non-Hodgkin's Lymphoma Drug Market by Type
  1. 4.1 Non-Hodgkin's Lymphoma Drug Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.2 Global Non-Hodgkin's Lymphoma Drug Sales Value by Type
  5. 4.2.1 Global Non-Hodgkin's Lymphoma Drug Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Non-Hodgkin's Lymphoma Drug Sales Value by Type (2021-2032)
  7. 4.2.3 Global Non-Hodgkin's Lymphoma Drug Sales Value Share by Type (2021-2032)
5 Non-Hodgkin's Lymphoma Drug Market by Application
  1. 5.1 Non-Hodgkin's Lymphoma Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Non-Hodgkin's Lymphoma Drug Sales Value by Application
  6. 5.2.1 Global Non-Hodgkin's Lymphoma Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Non-Hodgkin's Lymphoma Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Non-Hodgkin's Lymphoma Drug Sales Value Share by Application (2021-2032)
6 Non-Hodgkin's Lymphoma Drug Regional Value Analysis
  1. 6.1 Global Non-Hodgkin's Lymphoma Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Non-Hodgkin's Lymphoma Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Non-Hodgkin's Lymphoma Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Non-Hodgkin's Lymphoma Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032)
  7. 6.3.2 North America Non-Hodgkin's Lymphoma Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Non-Hodgkin's Lymphoma Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Non-Hodgkin's Lymphoma Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032)
  16. 6.6.2 South America Non-Hodgkin's Lymphoma Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Non-Hodgkin's Lymphoma Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Non-Hodgkin's Lymphoma Drug Sales Value Share by Country, 2025 VS 2032
7 Non-Hodgkin's Lymphoma Drug Country-level Value Analysis
  1. 7.1 Global Non-Hodgkin's Lymphoma Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Non-Hodgkin's Lymphoma Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Non-Hodgkin's Lymphoma Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Non-Hodgkin's Lymphoma Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Non-Hodgkin's Lymphoma Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Non-Hodgkin's Lymphoma Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Non-Hodgkin's Lymphoma Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Acrotech Biopharma
  2. 8.1.1 Acrotech Biopharma Company Information
  3. 8.1.2 Acrotech Biopharma Business Overview
  4. 8.1.3 Acrotech Biopharma Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Acrotech Biopharma Non-Hodgkin's Lymphoma Drug Product Portfolio
  6. 8.1.5 Acrotech Biopharma Recent Developments
  7. 8.2 Eagle Pharmaceuticals
  8. 8.2.1 Eagle Pharmaceuticals Company Information
  9. 8.2.2 Eagle Pharmaceuticals Business Overview
  10. 8.2.3 Eagle Pharmaceuticals Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eagle Pharmaceuticals Non-Hodgkin's Lymphoma Drug Product Portfolio
  12. 8.2.5 Eagle Pharmaceuticals Recent Developments
  13. 8.3 Epizyme
  14. 8.3.1 Epizyme Company Information
  15. 8.3.2 Epizyme Business Overview
  16. 8.3.3 Epizyme Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Epizyme Non-Hodgkin's Lymphoma Drug Product Portfolio
  18. 8.3.5 Epizyme Recent Developments
  19. 8.4 Gilead Sciences
  20. 8.4.1 Gilead Sciences Company Information
  21. 8.4.2 Gilead Sciences Business Overview
  22. 8.4.3 Gilead Sciences Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Gilead Sciences Non-Hodgkin's Lymphoma Drug Product Portfolio
  24. 8.4.5 Gilead Sciences Recent Developments
  25. 8.5 MundiPharma
  26. 8.5.1 MundiPharma Company Information
  27. 8.5.2 MundiPharma Business Overview
  28. 8.5.3 MundiPharma Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 MundiPharma Non-Hodgkin's Lymphoma Drug Product Portfolio
  30. 8.5.5 MundiPharma Recent Developments
  31. 8.6 Secura Bio
  32. 8.6.1 Secura Bio Company Information
  33. 8.6.2 Secura Bio Business Overview
  34. 8.6.3 Secura Bio Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Secura Bio Non-Hodgkin's Lymphoma Drug Product Portfolio
  36. 8.6.5 Secura Bio Recent Developments
  37. 8.7 TG Therapeutics
  38. 8.7.1 TG Therapeutics Company Information
  39. 8.7.2 TG Therapeutics Business Overview
  40. 8.7.3 TG Therapeutics Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 TG Therapeutics Non-Hodgkin's Lymphoma Drug Product Portfolio
  42. 8.7.5 TG Therapeutics Recent Developments
  43. 8.8 Bayer
  44. 8.8.1 Bayer Company Information
  45. 8.8.2 Bayer Business Overview
  46. 8.8.3 Bayer Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bayer Non-Hodgkin's Lymphoma Drug Product Portfolio
  48. 8.8.5 Bayer Recent Developments
  49. 8.9 Roche
  50. 8.9.1 Roche Company Information
  51. 8.9.2 Roche Business Overview
  52. 8.9.3 Roche Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Roche Non-Hodgkin's Lymphoma Drug Product Portfolio
  54. 8.9.5 Roche Recent Developments
  55. 8.10 Teva
  56. 8.10.1 Teva Company Information
  57. 8.10.2 Teva Business Overview
  58. 8.10.3 Teva Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Teva Non-Hodgkin's Lymphoma Drug Product Portfolio
  60. 8.10.5 Teva Recent Developments
  61. 8.11 Eisai
  62. 8.11.1 Eisai Company Information
  63. 8.11.2 Eisai Business Overview
  64. 8.11.3 Eisai Non-Hodgkin's Lymphoma Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Eisai Non-Hodgkin's Lymphoma Drug Product Portfolio
  66. 8.11.5 Eisai Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst